These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 29893893)

  • 41. Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy.
    Chiu SM; Kuo YH; Wang JH; Hung CH; Hu TH; Lu SN; Chen CH
    Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2989-2997.e3. PubMed ID: 32353534
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection.
    Zuo SR; Zuo XC; Wang CJ; Ma YT; Zhang HY; Li ZJ; Song LY; Deng ZZ; Liu SK
    J Clin Pharmacol; 2015 Mar; 55(3):288-97. PubMed ID: 25293471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
    Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ
    Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
    Doğan ÜB; Kara B; Gümürdülü Y; Soylu A; Akin MS
    Turk J Gastroenterol; 2012 Jun; 23(3):247-52. PubMed ID: 22798114
    [TBL] [Abstract][Full Text] [Related]  

  • 45. On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B.
    Huang YJ; Chang CS; Peng YC; Yeh HZ; Yang SS
    PLoS One; 2017; 12(3):e0174046. PubMed ID: 28350873
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
    Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
    Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term virological outcome in chronic hepatitis B patients with a partial virological response to entecavir.
    Jo YJ; Kim KA; Lee JS; Kim NH; Bae WK; Song TJ; Kim JW
    Korean J Intern Med; 2015 Mar; 30(2):170-6. PubMed ID: 25750558
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
    Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
    Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir.
    Fang HW; Yen YH; Hung CH; Wang JH; Hu TH; Lu SN; Chen CH
    Dig Dis Sci; 2022 Jul; 67(7):3402-3411. PubMed ID: 34241753
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy.
    Lin TC; Chiu YC; Chiu HC; Liu WC; Cheng PN; Chen CY; Chang TT; Wu IC
    World J Gastroenterol; 2018 Feb; 24(6):725-736. PubMed ID: 29456411
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment.
    Ma TL; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
    PLoS One; 2019; 14(10):e0222221. PubMed ID: 31584951
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice.
    Ha NB; Trinh HN; Rosenblatt L; Nghiem D; Nguyen MH
    J Clin Gastroenterol; 2016 Feb; 50(2):169-74. PubMed ID: 26018133
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients.
    Jeng WJ; Sheen IS; Chen YC; Hsu CW; Chien RN; Chu CM; Liaw YF
    Hepatology; 2013 Dec; 58(6):1888-96. PubMed ID: 23744454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Why not to stop antiviral treatment in patients with chronic hepatitis B.
    Marciano S; Gadano A
    Liver Int; 2018 Feb; 38 Suppl 1():97-101. PubMed ID: 29427480
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
    Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
    J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
    Lee S; Ahn SH; Jung KS; Kim DY; Kim BK; Kim SU; Baatarkhuu O; Ku HJ; Han K; Park JY
    J Viral Hepat; 2017 Feb; 24(2):141-147. PubMed ID: 27766731
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse.
    Tseng TN; Kuo YH; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
    Viruses; 2022 May; 14(6):. PubMed ID: 35746660
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B: From an "option" to an "active recommendation".
    Liaw YF; Chien RN
    Kaohsiung J Med Sci; 2022 Apr; 38(4):295-301. PubMed ID: 35262284
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice.
    Ridruejo E; Marciano S; Galdame O; Reggiardo MV; Muñoz AE; Adrover R; Cocozzella D; Fernandez N; Estepo C; Mendizabal M; Romero GA; Levi D; Schroder T; Paz S; Fainboim H; Mandó OG; Gadano AC; Silva MO
    Ann Hepatol; 2014; 13(3):327-36. PubMed ID: 24756007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.